- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sonus heads north to ATL territory
Ultrasound contrast agent developerSonus Pharmaceuticals is moving its corporate headquarters thismonth. The move, to the Seattle suburb of Bothell, WA, will makeSonus a close neighbor of ultrasound company ATL, also based inBothell. Sonus previously
Ultrasound contrast agent developerSonus Pharmaceuticals is moving its corporate headquarters thismonth. The move, to the Seattle suburb of Bothell, WA, will makeSonus a close neighbor of ultrasound company ATL, also based inBothell.
Sonus previously was headquartered in Costa Mesa, CA. The company,founded by Omniscan inventor Dr. Steven Quay, is developing aline of intravascular ultrasound contrast agents.
The company's first agent, EchoGen, is based on an emulsionthat turns into echogenic microbubbles when injected (SCAN 1/19/94).Sonus filed an investigational new drug (IND) application forEchoGen earlier this year.
The ATL and Sonus facilities are located within a stone's throwof each other, according to ATL president David Perozek. WhileATL and Sonus employees can look forward to sharing the sunnyskies for which the Pacific Northwest is famous, the relationshipbetween the companies will go no farther than that, at least forthe time being.
ATL and Sonus do not have a business relationship and haveno plans to develop one in the near future, Perozek said.
Sonus representatives were not available for comment.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
